TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20958995

Group type: EXPERIMENTAL
Intervention: Hands-on passive stretching treatment procedures directed to the talocrural joint, varying in treatment speed, during the post-acute injury period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hands-on placebo control intervention.
Number of subjects: 0
Study: 19934802

Group type: EXPERIMENTAL
Intervention: DC electrical stimulation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no DC electrical stimulation)
Number of subjects: 107
Study: 16968578

Group type: EXPERIMENTAL
Intervention: ALN + D (alendronate 70 mg and cholecalciferol 70 microg)
Number of subjects: 717

Group type: COMPARATOR
Intervention: ALN (alendronate 70 mg)
Number of subjects: 717
Study: 15367828

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 3000
Study: 11388527

Group type: EXPERIMENTAL
Intervention: Transfusion algorithm group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 9241384

Group type: EXPERIMENTAL
Intervention: 5-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 4 days, total 1200 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 7-day treatment regimen with sodium artesunate (400 mg on day 1, then 200 mg daily for 6 days, total 1600 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both regimens (5-day and 7-day)
Number of subjects: 91
Study: 8493946

Group type: COMPARATOR
Intervention: Conventional disinfection (70% isopropyl pads and povidone iodine saturated swabs)
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: PREP method (70% isopropyl/10% acetone scrub and povidone iodine dispenser)
Number of subjects: 1546
Study: 3545368

Group type: EXPERIMENTAL
Intervention: Peritoneum closed
Number of subjects: 206

Group type: COMPARATOR
Intervention: Peritoneum left open
Number of subjects: 206

Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 206
Study: 28505317

Group type: EXPERIMENTAL
Intervention: Light-curable fluoride varnish (LCFV)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional fluoride varnish
Number of subjects: 22
Study: 27502729

Group type: EXPERIMENTAL
Intervention: FEC → D (epirubicin 75 mg/m², 5-fluorouracil 500 mg/m², cyclophosphamide 500 mg/m² every 2 weeks for 4 cycles, followed by docetaxel 75 mg/m² every 2 weeks for 4 cycles)
Number of subjects: 650

Group type: COMPARATOR
Intervention: TC (docetaxel 75 mg/m² and cyclophosphamide 600 mg/m² every 21 days for 6 cycles)
Number of subjects: 650

Group type: COMPARATOR
Intervention: TC
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: FEC → D
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: FEC → D and TC
Number of subjects: 650
Study: 24612304

Group type: EXPERIMENTAL
Intervention: Polyacrylate-based hydrogel (n = 34)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Amorphous hydrogel (control group, n = 41)
Number of subjects: 75
Study: 22895449

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Multifactorial intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 116
Study: 20814844

Group type: EXPERIMENTAL
Intervention: Prefeeding oral stimulation program (5-min duration)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prefeeding oral stimulation program
Number of subjects: 19
Study: 19211712

Group type: EXPERIMENTAL
Intervention: 128 mg/d candesartan
Number of subjects: 269

Group type: COMPARATOR
Intervention: 16 mg/d candesartan
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 64 mg/d candesartan
Number of subjects: 269
Study: 15895882

Group type: EXPERIMENTAL
Intervention: Infliximab + Methotrexate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Methotrexate alone after stopping infliximab
Number of subjects: 26
Study: 12703866

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study: 10475315

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 800 microg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 10 mg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Oral transmucosal fentanyl citrate (OTFC) 200 microg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Intravenous morphine 2 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 800 microg and Intravenous morphine 10 mg
Number of subjects: 133
Study: 8704237

Group type: EXPERIMENTAL
Intervention: XomaZyme-CD5 Plus
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 1857135

Group type: EXPERIMENTAL
Intervention: Nurses referring patients directly based on positive screening results
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Standard care by physicians
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: Patients briefly introduced to the alcohol counselor at the time of referral
Number of subjects: 1328
Study: 6213382

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenoterol plus theophylline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triple combination (ipratropium bromide + fenoterol + theophylline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Triple combination
Number of subjects: 30
Study: 30953836

Group type: EXPERIMENTAL
Intervention: Contingent neurofeedback information from their own brain signals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-contingent neurofeedback information from matched participants
Number of subjects: 60
Study: 28437196

Group type: EXPERIMENTAL
Intervention: Skin anti-sepsis intervention
Number of subjects: 787
Study: 24936937

Group type: EXPERIMENTAL
Intervention: Elevated umbilical cord serum IL-8 and IL-1β levels in infants with low MDI
Number of subjects: 615

Group type: COMPARATOR
Intervention: Cord serum cytokine levels (IL-8, IL-1β, TNF-α)
Number of subjects: 615
Study: 23333168

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (HA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (HA) without concomitant shoulder pathologies
Number of subjects: 300
Study: 19819118

Group type: EXPERIMENTAL
Intervention: Olive oil meal (36% MUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Walnut meal (16% PUFA, 4% α-linolenic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Butter meal (35% SFA)
Number of subjects: 0
Study: 19864673

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (2 mg of trimethoprim plus 10 mg of sulfamethoxazole per kilogram of body weight) for 12 months
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 576
Study: 17080491

Group type: EXPERIMENTAL
Intervention: Flexible method for extensions of fixed sample or group-sequential trials with t-distributed test statistics
Number of subjects: 0
Study: 12743236

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 400 mg/d
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Valproate (VPA) 2,250 mg/d
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 11093007

Group type: EXPERIMENTAL
Intervention: rHu‐EPO (200 units/kg every other day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no rHu‐EPO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: rHu‐EPO
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pre-transfusion
Number of subjects: 36
Study: 9170385

Group type: EXPERIMENTAL
Intervention: Synthes reconstruction nail
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zimmer reconstruction nail
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Richards reconstruction nail
Number of subjects: 18
Study: 1487624

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2439813

Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Slow-release oxprenolol
Number of subjects: 22
Study: 30428601

Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) technology applied to develop SSR markers
Number of subjects: 24
Study: 27266868

Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention consisting of two one-hour individualized sessions focusing on CHD knowledge and self-management skills.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nurse-led transition intervention
Number of subjects: 120
Study: 24341301

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 469

Group type: COMPARATOR
Intervention: Vortioxetine 2.5 mg
Number of subjects: 469

Group type: COMPARATOR
Intervention: Vortioxetine 5 mg
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 22561658

Group type: EXPERIMENTAL
Intervention: Selective pulsatile pulmonary perfusion (sPPP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 64
Study: 20713848

Group type: EXPERIMENTAL
Intervention: Four cycles of BEACOPP(baseline) + 20 Gy of IFRT
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Four cycles of BEACOPP(baseline) + 30 Gy of IFRT
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Four cycles of ABVD + 20 Gy of IFRT
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Four cycles of ABVD + 30 Gy of IFRT
Number of subjects: 1395
Study: 18621986

Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam 75 microg kg(‐1) (Group M)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg (Group K)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg + Midazolam 37.5 microg kg(‐1) (Group KM)
Number of subjects: 120
Study: 16098435

Group type: EXPERIMENTAL
Intervention: Tadalafil (100 mg by mouth)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ibutilide (0.002 mg/kg intravenously)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12453953

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.i.d.)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 10392984

Group type: EXPERIMENTAL
Intervention: Genotypic-resistance testing (n=65)
Number of subjects: 108
Study: 9746445

Group type: EXPERIMENTAL
Intervention: Benzodiazepine group (clonazepam or alprazolam)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Benzodiazepine group
Number of subjects: 13
Study: 1667908

Group type: EXPERIMENTAL
Intervention: Papilla preservation flap
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional flap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Granular hydroxyapatite
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no granular hydroxyapatite)
Number of subjects: 10
Study: 6758474

Group type: EXPERIMENTAL
Intervention: Cemented prosthesis
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-cemented prosthesis
Number of subjects: 112
Study: 31094746

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (30 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dextromethorphan and Placebo
Number of subjects: 20
Study: 28056945

Group type: EXPERIMENTAL
Intervention: Locally produced lipid-based nutrient supplement (Wawamum) for children 6-23 months, micronutrient powders for children 24-59 months, and wheat soya blends for pregnant and lactating mothers.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Food-based interventions delivered by government lady health workers.
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Cross-sectional surveys and community-based cluster randomized controlled trial.
Number of subjects: 5000
Study: 26253828

Group type: EXPERIMENTAL
Intervention: NMES (ESG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study: 24121757

Group type: COMPARATOR
Intervention: TMC310911 (75‐2000 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: TMC310911 (300 mg bid, 600 mg once daily, 150 mg bid plus 100 mg ritonavir bid, 900 mg bid alone, 300 mg bid plus ritonavir 50 mg bid)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TMC310911 (1200 mg single-dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TMC310911 coadministered with ritonavir
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TMC310911 (up to 2000 mg) and multiple-dose (up to 900 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TMC310911 with or without ritonavir
Number of subjects: 26
Study: 22549597

Group type: EXPERIMENTAL
Intervention: Internal perspective imagery training
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: External perspective imagery training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Relaxation imagery training (Control)
Number of subjects: 19
Study: 20518332

Group type: EXPERIMENTAL
Intervention: MCV-A/C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17961366

Group type: EXPERIMENTAL
Intervention: Bonded filling material
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Unbonded filling material
Number of subjects: 115
Study: 15642807

Group type: EXPERIMENTAL
Intervention: Ramosetron 3 microg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ramosetron 6 microg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ramosetron 12 microg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12490857

Group type: EXPERIMENTAL
Intervention: MIVAT (Minimally Invasive Video-Assisted Thyroidectomy)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional near-total thyroidectomy
Number of subjects: 33
Study: 9836062

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combat control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncombat control group
Number of subjects: 0
Study: 7859961

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (2 L/minute) via nasal cannula
Number of subjects: 201

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Midazolam and meperidine
Number of subjects: 201
Study: 2785813

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7446041

Group type: EXPERIMENTAL
Intervention: High tibial osteotomy with 5 degrees overcorrection of varus deformity
Number of subjects: 78

Group type: COMPARATOR
Intervention: High tibial osteotomy with normal correction of varus deformity
Number of subjects: 78
Study: 31942744

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (0.5 mL/kg bupivacaine 0.25% every eight hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol (15 mg/kg intravenously every eight hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0
Study: 30884335

Group type: EXPERIMENTAL
Intervention: Music therapy for 10 days
Number of subjects: 15
Study: 28299294

Group type: EXPERIMENTAL
Intervention: Chamomile cream (0.5 g applied twice a day for 10 days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo cream (applied twice a day for 10 days)
Number of subjects: 114
Study: 25209868

Group type: EXPERIMENTAL
Intervention: Methotrexate plus pioglitazone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 44
Study: 23559220

Group type: EXPERIMENTAL
Intervention: paliperidone ER
Number of subjects: 80

Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 80
Study: 21327805

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2.5 μg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Melatonin 0.1 mg/kg
Number of subjects: 100
Study: 19930021

Group type: EXPERIMENTAL
Intervention: Day/Residential services (n = 42)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Outpatient services (n = 37)
Number of subjects: 184
Study: 16896874

Group type: EXPERIMENTAL
Intervention: Microcurrent skin patch (MCT) plus tramadol hydrochloride
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tramadol hydrochloride (control)
Number of subjects: 24
Study: 16388069

Group type: EXPERIMENTAL
Intervention: 1 g/day ethyl-EPA
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2 g/day ethyl-EPA
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 12748973

Group type: EXPERIMENTAL
Intervention: GP+EX (Group Psychotherapy plus Home-based Exercise)
Number of subjects: 108

Group type: COMPARATOR
Intervention: GP (Group Psychotherapy)
Number of subjects: 108
Study: 11098244

Group type: EXPERIMENTAL
Intervention: LHRH agonists
Number of subjects: 184500

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade
Number of subjects: 184500

Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiandrogen
Number of subjects: 184500

Group type: EXPERIMENTAL
Intervention: Primary androgen suppression initiated at diagnosis
Number of subjects: 184500
Study: 8735863

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 micrograms daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bronchodilators only
Number of subjects: 16
Study: 1768820

Group type: EXPERIMENTAL
Intervention: Sodium thiopental (3 mg/kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Etomidate (0.15 mg/kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 44
Study: 6803909

Group type: EXPERIMENTAL
Intervention: High doses (regimen I)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Very high doses (regimen II)
Number of subjects: 91
Study: 30596649

Group type: EXPERIMENTAL
Intervention: Linear-spatial materials (discrete squares arranged in rows)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Irregular materials (pictures of stars arranged in random arrays)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Linear-spatial materials
Number of subjects: 29
Study: 27912940

Group type: EXPERIMENTAL
Intervention: Panax ginseng and Salvia miltiorrhiza supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Eccentric resistance training (both groups)
Number of subjects: 23
Study: 26107836

Group type: EXPERIMENTAL
Intervention: Massage and electromechanical pumping
Number of subjects: 16
Study: 22417254

Group type: COMPARATOR
Intervention: Ingenol mebutate gel (0.015% for face and scalp, 0.05% for trunk and extremities), self-applied to a 25-cm² contiguous field once daily for 3 consecutive days (face/scalp) or 2 consecutive days (trunk/extremities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ingenol mebutate gel
Number of subjects: 0
Study: 21086591

Group type: EXPERIMENTAL
Intervention: Magnetolaser therapy in combination with whole body iodine‐bromide‐sodium chlorine baths, physical exercises, and massage
Number of subjects: 67
Study: 19014552

Group type: EXPERIMENTAL
Intervention: Education program (structured dialogue conveying information about pathophysiology, pharmacological and non‐pharmacological treatment of GERD, patients' rights and use of healthcare)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Education program (knowledge test score)
Number of subjects: 211
Study: 15724034

Group type: EXPERIMENTAL
Intervention: Low supplementation throughout (group LL)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: High supplementation throughout (group HH)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Low until day 10 and then high (group LH)
Number of subjects: 119
Study: 11842293

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for 3 years
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (open control)
Number of subjects: 205
Study: 12198784

Group type: EXPERIMENTAL
Intervention: Phoneme sharing condition (first phoneme shared)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phoneme sharing condition (last phoneme shared)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual route cascaded model of reading
Number of subjects: 0
Study: 7475039

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sober
Number of subjects: 128
Study: 1723461

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once daily for 4 months)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Enalapril (20 mg once daily for 4 months)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nitrendipine and Enalapril
Number of subjects: 52
Study: 6756533

Group type: COMPARATOR
Intervention: iopamidol (Niopam)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: sodium meglumine ioxaglate (Hexabrix)
Number of subjects: 50
Study: 30422259

Group type: EXPERIMENTAL
Intervention: DIL intervention (depression in later life intervention)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: DIL intervention
Number of subjects: 181
Study: 28632867

Group type: EXPERIMENTAL
Intervention: WIC program plus a 12-month primarily internet-based weight loss program
Number of subjects: 371

Group type: COMPARATOR
Intervention: WIC program (standard care group)
Number of subjects: 371
Study: 25801231

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa preparation (PAP)
Number of subjects: 72